KRYS Research | Milton Maxwell

KRYS

Krystal Biotech, Inc.

238.55

-4.43-1.82%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

FY Q4 '25

Ex-US hurdles detailed, no buybacks

2/16/26Feb 16, 2026

Q&A drilled into ex-US launch hurdles, clarifying conservative accruals in Germany (pricing by H2 2026) and France (H1 2027) will make revenue lag patient adds, while Japan's two-week prescription rule burdens early compliance. US demand accelerates yet patients shift to intermittent dosing. Management nixed near-term M&A or in-licensing, holding cash for pipeline before buybacks. No buybacks soon. Protocol tweaks for KB801 and KB803 boost home-dosing flexibility without derailing timelines. Investors will track Q1 US/ex-US splits and international pricing.

Key Stats

Market Cap

6.92B

P/E (TTM)

35.71

Basic EPS (TTM)

6.68

Dividend Yield

Recent Filings

10-K

FY2025 results

2/17/26Feb 17, 2026

Krystal Biotech delivered FY2025 net product revenue of $389.1 million from VYJUVEK, up 34% y/y, with gross margins holding steady at 94% thanks to manufacturing optimizations. Q4 sales accelerated sequentially, fueled by U.S. growth and launches in Germany, France, and Japan amid ongoing EU pricing talks. R&D expenses ticked up 8% to $58.0 million, driven by KB707 oncology combo trials and new ophthalmology/dermatology programs, while SG&A rose 29% to support global commercialization. Cash hit $827.8 million, funding runway through pipeline milestones. VYJUVEK remains substantially dependent on commercial success.

8-K

Q4 revenue hits $107M

2/17/26Feb 17, 2026

Krystal Biotech posted $107.1M Q4 VYJUVEK revenue, up from $91.1M, driving $389.1M full-year sales and $51.4M net income versus $45.5M prior year. Cash swelled to $955.9M. FDA awarded RMAT to KB707 for NSCLC, Fast Track to KB111 for HHD. Pipeline advances fast.

8-K

VYJUVEK revenue $388-389M

1/12/26Jan 12, 2026

Krystal Biotech unveiled preliminary 2025 results: VYJUVEK net revenue hit $388-389M for the year, $106-107M in Q4, with cash at $955M. Cash fuels rare disease push—four marketed drugs by 2030. 2026 non-GAAP R&D/SG&A guidance: $175-195M. Numbers preliminary, subject to audit tweaks.

8-K

KB407 confirms CFTR delivery

1/8/26Jan 8, 2026

Krystal Biotech disclosed positive interim Phase 1 CORAL-1 data on January 8, 2026, confirming KB407 delivered wild-type CFTR to lungs of all six analyzed CF patients, with 29.4%-42.1% conducting airway cells transduced regardless of modulator status. KB407 was well-tolerated, with only mild-to-moderate adverse events. CORAL-3 repeat-dosing study, submitted to FDA, eyes enrollment in 1H 2026. Lung platform validated.

8-K

Director Ganorkar resigns

12/23/25Dec 23, 2025

Krystal Biotech's board loses Kirti Ganorkar, who resigned December 22, 2025, citing time constraints from his Sun Pharma promotion—no disagreements with management. He served since the 2017 IPO and exits fully December 31. Smooth transition underscores steady governance.

About

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

CEO

Mr. Krish S. Krishnan M.B.A., M.S.

IPO

9/20/2017

Website

https://www.krystalbio.com

Employees

275

Sector

Healthcare

Industry

Biotechnology